Register for free to listen to this article
Listen with Speechify
0:00
2:00
CONSHOHOCKEN, Pa.—Instem, a provider of IT solutions to the global early development healthcare market, recently announced that the Shanghai Institute of Planned Parenthood Research (National Evaluation Centre for the Toxicology of Fertility Regulating Drugs), or SIPPR-NTC, has purchased the Provantis Reproductive Toxicology software solution to automate processes at its Shanghai facility.
 
SIPPR-NTC’s investment in Provantis is expected to further streamline its research processes and deliver increased efficiencies in the collection, storage and reporting of key research data.
 
“We are delighted to be deploying Instem’s world-leading Provantis software solution at our Shanghai facility,” said Dr. Zu-Yue Sun, director of SIPPR-NTC. “SIPPR-NTC has exciting growth plans for the future, and we see our partnership with Instem and our investment in Provantis as a key component of our growth strategy.”
 
Neil Donaldson, vice president of sales for Europe and Asia at Instem, added, “We are extremely pleased to welcome SIPPR-NTC to our Provantis user community. SIPPR-NTC is recognized as a leading organization within their field, and it is a great honor that they have chosen Instem to support them in their growth plans.”
 
The contract was awarded following a formal competitive tender, with, as Instem reported, “Provantis recognized as the overwhelming standard within China and the leading solution around the world.” Under the deal, Instem was to implement a full turnkey solution, including hardware and software deployment, and for its part, SIPPR has, as Instem noted, “purchased a range of professional services to facilitate quicker implementation and faster return on investment.”
 
Founded in 1978, SIPPR-NTC is recognized as a center of excellence in the area of reproductive health and is one of the major collaborating centers of the World Health Organization’s HRP program. HRP is the main instrument within the United Nations system for research in human reproduction, bringing together policy-makers, scientists, healthcare providers, clinicians, consumers and community representatives to identify and address priorities for research to improve reproductive health.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue